Opponents of abortion in the United States are increasing pressure on the Food and Drug Administration (FDA) under President Donald Trump’s administration to impose tighter restrictions on the abortion pill mifepristone, particularly its availability via telehealth and mail delivery. Advocates argue that the widespread online prescribing of the medication undermines state-level abortion bans, fueling frustration over what they perceive as slow federal action.

This tension came into sharper focus following a recent court ruling in a lawsuit filed by Louisiana Attorney General Liz Murrill against the FDA. U.S. District Judge David Joseph, a Trump appointee, indicated that Louisiana presented a strong case challenging the agency’s policies but stopped short of immediately halting telehealth prescriptions of mifepristone. The case centers on efforts to curb FDA rules that have increased access to the abortion pill, including allowing it to be prescribed without an in-person appointment.

Louisiana and other states with total or near-total abortion bans claim that the availability of mifepristone through online providers weakens their ability to enforce these restrictions. Since the U.S. Supreme Court’s 2022 decision overturning Roe v. Wade, 13 states have banned abortion at all stages with limited exceptions, but some Democratic-controlled states have enacted "shield laws" to protect healthcare providers who prescribe abortion pills remotely or mail them to states where abortion is restricted. These conflicting state laws have triggered ongoing legal challenges.

During Tuesday’s ruling, Judge Joseph noted that while he would not immediately block telehealth prescriptions, the plaintiffs could eventually prevail, citing the state's "irreparable harm." He also directed the FDA to provide a progress update on its ongoing review of mifepristone within six months. Murrill subsequently announced plans to escalate the case to the U.S. Court of Appeals for the Fifth Circuit, seeking expedited action.

Anti-abortion advocates, including figures like Family Research Council President Tony Perkins, have praised the legal steps and urged the Trump administration to expedite restrictions on the drug. Perkins expressed concern that the number of abortions has not declined since the Supreme Court’s ruling, warning of a potential loss of support among conservative voters ahead of the upcoming midterm elections.

However, some anti-abortion leaders remain cautiously optimistic that the administration will act appropriately. National Right to Life’s Madison LaClare voiced trust in the FDA’s review process, while Susan B. Anthony Pro-Life America’s Marjorie Dannenfelser emphasized the administration’s opportunity to prioritize women’s safety without criticizing it directly.

Recent election results suggest a political landscape more favorable to abortion rights than to bans, with voters rejecting restrictive measures in 14 of 17 states where the issue appeared on ballots since Roe was overturned. Legal experts note an emerging public consensus opposing comprehensive abortion bans.

The FDA confirmed it is conducting a thorough safety evaluation of mifepristone, involving extensive data collection and review processes that could extend beyond a year, but the agency intends to complete the review more quickly. The agency did not specify when the review began.

Mifepristone was initially approved in 2000 with strict distribution limits, such as requiring prescribed administration by certified physicians following in-person consultations due to risks like excessive bleeding. During the COVID-19 pandemic, those restrictions were eased after studies indicated the pill's safety in less supervised contexts, allowing prescriptions via telehealth and mail—a change at the heart of the current controversies.

The heightened scrutiny over mifepristone coincides with increased political attention under the Trump administration and Health Secretary Robert F. Kennedy Jr., whose confirmation hearing last year included several inquiries from Republican lawmakers about the drug’s safety and regulatory status. The FDA’s approval last fall of another generic version of mifepristone further intensified dissatisfaction among abortion opponents seeking tighter controls.